Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529822 · ClinicalTrials.gov registry record · Phase 1
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
A Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06529822: Recruiting Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma, sponsored by Washington University School of Medicine.
NCT06529822 is a Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 32 participants, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06529822, a Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Conditions Studied
Interventions
- BIOLOGICAL Synthetic long peptide personalized cancer vaccine
- DRUG Poly ICLC
- DEVICE Signatera assay
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2033-03-31 |
| Phase | Phase 1 |
What NCT06529822 shows while recruiting
NCT06529822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Synthetic long peptide personalized cancer vaccine is the first listed.
NCT06529822 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06529822 about?
NCT06529822 is a clinical study titled "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease". This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and cap...
What is the current status of trial NCT06529822?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-03-20. Estimated completion is 2033-03-31.
What conditions does trial NCT06529822 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT06529822?
The interventions under investigation include: Synthetic long peptide personalized cancer vaccine (BIOLOGICAL), Poly ICLC (DRUG), Signatera assay (DEVICE).
Who is sponsoring clinical trial NCT06529822?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529822 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06529822's enrollment target sits among peer trials
32 10th of 14 higher than 5 of 14 other Muscle-Invasive Bladder Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle-Invasive Bladder Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Prophylactic Antibiotics in Cystectomy With Diversion
RECRUITING · Early Phase 1
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI